Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823911 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
A Phase 4 study of HIV and Cardiovascular Diseases, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
- 2
- Study locations
NCT03823911 is a Phase 4 study of HIV and Cardiovascular Diseases that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 87 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03823911, a Phase 4 study of HIV and Cardiovascular Diseases, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.
Conditions Studied
Interventions
- PROCEDURE Cardiac MRI
- DRUG Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Study Locations (2)
District of Columbia
- Unity Parkside Health Center - Washington D.C.
Maryland
- Institute of Human Virology, CRU - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-11-18 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03823911
The ClinicalTrials.gov registry entry for NCT03823911 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Cardiac MRI is the first listed.
NCT03823911 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03823911 about?
NCT03823911 is a clinical study titled "Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication". This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and...
What is the current status of trial NCT03823911?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2018-11-18. Estimated completion is 2022-12-31.
What conditions does trial NCT03823911 study?
This clinical trial studies the following conditions: HIV, Cardiovascular Diseases, Hepatitis C.
What interventions are being tested in trial NCT03823911?
The interventions under investigation include: Cardiac MRI (PROCEDURE), Elbasvir / Grazoprevir Oral Tablet [Zepatier] (DRUG).
Who is sponsoring clinical trial NCT03823911?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03823911 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.